Sequencing Considerations in the Third-Line Treatment of Metastatic Colorectal Cancer

Rákkutatás · Colorectal cancer

Four FDA‑approved 3L+ treatment options currently exist in the United States including regorafenib, FTD/TPI alone or with bevacizumab, and fruquintinib.

Four FDA‑approved third‑line or later (3L+) therapeutic options for metastatic colorectal cancer (mCRC) are currently available in the United States: regorafenib, trifluridine/tipiracil (FTD/TPI) alone or combined with bevacizumab, and fruquintinib. No single sequence is universally recommended by current NCCN Guidelines, underscoring the need for data‑driven sequencing strategies. The article reviews evidence, toxicity profiles, and economic implications of these agents, and discusses the challenges of sequencing in the 3L+ setting.

Choosing an effective sequence of these agents is critical to optimizing survival while preserving quality of life and managing cumulative toxicity, especially hematologic myelosuppression. Current guidelines do not define a single optimal path, leaving clinicians and payers to rely on indirect evidence and case‑by‑case judgment.

Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Eredeti forrás

Kapcsolódó jelek